Evaluating Safety and efficacy in retrospective ANAlysis after switching Drug to topiroxostat Among patients with hyperuricemia study
- Conditions
- gouty or hyperuricemia
- Registration Number
- JPRN-UMIN000023584
- Lead Sponsor
- Houden Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
Patients who fall into any of the following criteria are excluded from participating in the study. 1. Patients who is hypersensitive to topiroxostat, febuxostat, or allopurinol 2. Dehydrated patients or patients with impairment in drinking water 3. Patients with rheumatic disease 4. Patients with COPD 5. Patients with idiopathic thrombocytopenic purpura (ITP) 6. Patients taking pyrazinamide or ethambutol while giving their samples 7. Patients taking mizoribine or cyclosporine while giving their samples 8. Patients taking mercaptopurine hydrate, or azathioprine while giving their samples 9. Patients taking xanthine-based medicine while giving their samples 10. Patients taking non-steroidal anti-inflammatory/NSAIDs drug while giving their samples 11. Other conditions that a physician thinks inappropriate to participate in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changed amount in L-FABP values from baseline to the week 24
- Secondary Outcome Measures
Name Time Method 1. Changed amount and rate from baseline to the week 24 in the values listed below: * Marker of renal function, such as albumin/creatinine ratio (ACR), beta 2-microglobulin (beta 2-MG) , urinary N/acetyl/beta/D/glucosaminidase (NAG) , cystatine C, and eGFR * BNP * remnant-like lipoprotein particle cholesterol (RLPC) * hs-CRP * Xanthine oxidoreductase * Xanthine * Hypoxanthin * IMT * PWV * Other, vital, general blood test, urine test 2. Incidence rate of AE, such as gouty arthritis